Columbus-based Invirsa develops INV-102, a drug candidate designed to help cells respond to DNA damage in ocular and respiratory conditions. Its approach uses a brief, predictable activation of p53 to support DNA repair while limiting inflammation, with clinical development focused on diabetic dry eye and other eye injuries. Invirsa is also collaborating with Nationwide Children’s to study INV-102 in lung disease and has a five-year, $29.6 million BARDA partnership supporting ocular injury work.
PhotoOpTxBased in Solon, Ohio, PhotoOpTx develops photobiomodulation medical devices and treatment protocols for retinal disorders, including its investigational Retilux laser therapy device for diabetic macular edema. The company’s work centers on non-pharmacological light-based approaches intended to address unmet needs in ophthalmology, with research conducted alongside organizations such as the Jaeb Center for Health Research and the DRCR Network.SOLON, OH
Amyndas PharmaceuticalsFounded by University of Pennsylvania complement researcher John D. Lambris, Amyndas Pharmaceuticals develops C3-targeted complement therapeutics for inflammatory and immune-mediated diseases. The company’s patented platform builds on compstatin, the peptide inhibitor discovered in Lambris’ laboratory, with lead programs including AMY-101 and newer candidates designed for longer-lasting treatment of conditions such as age-related macular degeneration.PHILADELPHIA, PA
Revitalize EnergyRevitalize Energy makes U.S.-manufactured eye drops for tired, dry and red eyes, using its patented Opti-Boost Technology in a compact formula designed for long days of screen use, work and driving. The company says its products are made in a registered facility following current good manufacturing practices, with the formulation, packaging and manufacturer registered in the National Drug Code Directory.PITTSBURGH, PA
VitaPixelBorn from retinal surgeon Christopher Riemann’s experience with a career-threatening neck injury, VitaPixel is developing a digital slit-lamp system that brings stereoscopic 3D viewing to XR glasses so ophthalmologists can examine patients upright. The Cincinnati-based team combines Riemann’s more than 25 years at the slit lamp with medical-device engineering and ophthalmic clinical experience. VitaPixel remains a pre-market startup; its device is not yet FDA-cleared or available for sale.